Stock of the Day

December 23, 2022

Iovance Biotherapeutics (IOVA)

$13.71
-$1.01 (-6.9%)
Market Cap: $6.22B

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Today's Trend

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has attracted investor attention after raising its 2026 revenue outlook, receiving higher analyst forecasts, and reaching more than two-year highs. The news points to improving commercial expectations for its TIL cancer therapy, although the company remains unprofitable and some valuation signals are mixed.

  • Higher revenue outlook supports the bull case. Iovance’s increased FY2026 revenue guidance is the main catalyst behind the recent advance, signaling stronger expectations for product demand and commercial execution. IOVA Stock Hits Over 2-Year Highs – Why Iovance Raised Its FY2026 Revenue Outlook
  • Analysts are improving earnings expectations. Zacks Research raised its FY2026 EPS forecast to a loss of $0.55 from $0.56, FY2027 to a loss of $0.39 from $0.44, and FY2028 to a loss of $0.03 from $0.07. Several quarterly estimates were also revised higher, with Q3 2028 projected at breakeven. HC Wainwright likewise raised its estimates, maintained a “Buy” rating, and kept a $20 price target. Analyst earnings estimates for Iovance Biotherapeutics
  • Additional analyst support is helping sentiment. Wells Fargo increased its price target, while the broader consensus target was reported as rising 34.74% to $13.06. Zacks’ earnings-surprise methodology also identified IOVA as a stock investors should monitor for a potential earnings beat. Iovance Biotherapeutics Stock Gets Price Target Increase from Wells Fargo
  • Management strengthened its medical leadership. Iovance appointed Noah Berkowitz, M.D., Ph.D., as chief medical officer, adding global drug-development experience in T-cell therapies. The appointment is strategically supportive but is unlikely to materially affect near-term results. Iovance Appoints Noah Berkowitz as Chief Medical Officer
  • Losses and valuation risks remain. Iovance is still expected to report a full-year loss, and the reported $13.06 consensus target is below the recent trading level. That gap could limit upside or increase volatility if revenue growth fails to meet elevated expectations.
← Previous Stock of the DayNext Stock of the Day →

Recent News